E112D polymorphism in the prolylcarboxypeptidase gene is associated with blood pressure response to benazepril in Chinese hypertensive patients  

作　　者：ZHANG Yan HONG Xiu-mei XING Hou-xun Li Jian-ping HUO Yong XU Xi-ping 

机构地区：[1]Department of Cardiology, Peking University First Hospital, Beijing 100034, China [2]Anlaui-Medical University Biomedical Institute, Hefei, Anhui 230032, China

出　　处：《Chinese Medical Journal》2009年第20期2461-2465,共5页中华医学杂志（英文版）

摘　　要：Background Marked interindividual variation exists in blood pressure response to benazepril, which is considered to have genetic basis. Our objectives were to evaluate whether the E112D polymorphism in the prolylcarboxypeptidase （PRCP） gene has impact on blood pressure response to benazepril. Methods Hypertensive patients from Huoqiu County and Yuexi County of Anhui Province received daily treatment with an oral dosage of 10 mg benazepril for 15 days. Genotypes of the E112D polymorphism in the PRCP gene were determined by TaqMan SNP genotyping assay. Multivariate linear and Logistic regressions using generalized estimating equation model were performed in a total of 1092 patients to evaluate the association of PRCP genotypes and blood pressure response to benazepril. Results Patients carrying ED or DD genotype had a less systolic blood pressure reduction （adjusted 13= -3.7±1.1, P 〈0.001）, a less diastolic blood pressure reduction （adjusted β= -3.1±0.8, P 〈0.001） and a lower percentage of reaching target blood pressure defined as SBP lower than 140 mmHg and DBP lower than 90 mmHg （adjusted OR=0.6, P=0.005） than those patients carrying EE genotype. In addition, the results from stratified analysis by county （Huoqiu or Yuexi） were similar to those observed in the pooled population. Conclusions Our data suggest that the E112D polymorphism in the PRCP gene may be a useful genetic marker to predict the antihypertensive effect of short-term benazepril treatment in hypertensive Datients of Anhui Province. China.Background Marked interindividual variation exists in blood pressure response to benazepril, which is considered to have genetic basis. Our objectives were to evaluate whether the E112D polymorphism in the prolylcarboxypeptidase （PRCP） gene has impact on blood pressure response to benazepril. Methods Hypertensive patients from Huoqiu County and Yuexi County of Anhui Province received daily treatment with an oral dosage of 10 mg benazepril for 15 days. Genotypes of the E112D polymorphism in the PRCP gene were determined by TaqMan SNP genotyping assay. Multivariate linear and Logistic regressions using generalized estimating equation model were performed in a total of 1092 patients to evaluate the association of PRCP genotypes and blood pressure response to benazepril. Results Patients carrying ED or DD genotype had a less systolic blood pressure reduction （adjusted 13= -3.7±1.1, P 〈0.001）, a less diastolic blood pressure reduction （adjusted β= -3.1±0.8, P 〈0.001） and a lower percentage of reaching target blood pressure defined as SBP lower than 140 mmHg and DBP lower than 90 mmHg （adjusted OR=0.6, P=0.005） than those patients carrying EE genotype. In addition, the results from stratified analysis by county （Huoqiu or Yuexi） were similar to those observed in the pooled population. Conclusions Our data suggest that the E112D polymorphism in the PRCP gene may be a useful genetic marker to predict the antihypertensive effect of short-term benazepril treatment in hypertensive Datients of Anhui Province. China.

关 键 词：BENAZEPRIL PROLYLCARBOXYPEPTIDASE POLYMORPHISM HYPERTENSION 

分 类 号：R686[医药卫生—骨科学]